280 related articles for article (PubMed ID: 16447135)
41. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age.
Nolan T; Bernstein H; Blatter MM; Bromberg K; Guerra F; Kennedy W; Pichichero M; Senders SD; Trofa A; Collard A; Sullivan DC; Descamps D
Pediatrics; 2006 Sep; 118(3):e602-9. PubMed ID: 16950952
[TBL] [Abstract][Full Text] [Related]
42. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee.
Santoli JM; Peter G; Arvin AM; Davis JP; Decker MD; Fast P; Guerra FA; Helms CM; Hinman AR; Katz R; Klein JO; Koslap-Petraco MB; Paradiso PR; Schaffner W; Whitley-Williams PN; Williamson DE; Gellin B;
JAMA; 2003 Dec; 290(23):3122-8. PubMed ID: 14679275
[TBL] [Abstract][Full Text] [Related]
43. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
44. The vexing problems of vaccine compensation.
Sun M
Science; 1985 Mar; 227(4690):1012-4. PubMed ID: 3975597
[TBL] [Abstract][Full Text] [Related]
45. What defines a public health emergency? An analysis of the strategic national stockpile and the National Childhood Vaccine Injury Act: the need for prevention of nonterror national medical emergencies.
Bhanot KK
J Contemp Health Law Policy; 2004; 21(1):137-67. PubMed ID: 15799537
[No Abstract] [Full Text] [Related]
46. Vaccination coverage among children in kindergarten--United States, 2006-07 school year.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2007 Aug; 56(32):819-21. PubMed ID: 17703172
[TBL] [Abstract][Full Text] [Related]
47. Simultaneous vaccination of Chinese applicants for a United States immigrant visa.
Hua L; Hongtao H; Shunqin W; Jinping G; Jiandong C; Zhaoliang L; Xinwen F
Travel Med Infect Dis; 2008 May; 6(3):130-6. PubMed ID: 18486068
[TBL] [Abstract][Full Text] [Related]
48. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
49. The FDA and the tort system: postmarketing surveillance, compensation, and the role of litigation.
Struve CT
Yale J Health Policy Law Ethics; 2005; 5(2):587-669. PubMed ID: 16052895
[No Abstract] [Full Text] [Related]
50. Compensation for vaccine injury: balancing society's need and personal risk.
Grabenstein JD
Hosp Pharm; 1995 Sep; 30(9):831-2, 834-6. PubMed ID: 10151285
[No Abstract] [Full Text] [Related]
51. Vaccine shortages: history, impact, and prospects for the future.
Hinman AR; Orenstein WA; Santoli JM; Rodewald LE; Cochi SL
Annu Rev Public Health; 2006; 27():235-59. PubMed ID: 16533116
[TBL] [Abstract][Full Text] [Related]
52. Vaccine shortages: why they occur and what needs to be done to strengthen vaccine supply.
Klein JO; Myers MG
Pediatrics; 2006 Jun; 117(6):2269-75. PubMed ID: 16740872
[No Abstract] [Full Text] [Related]
53. Safety and immunogenicity of a pentavalent vaccine compared with separate administration of licensed equivalent vaccines in US infants and toddlers and persistence of antibodies before a preschool booster dose: a randomized, clinical trial.
Guerra FA; Blatter MM; Greenberg DP; Pichichero M; Noriega FR;
Pediatrics; 2009 Jan; 123(1):301-12. PubMed ID: 19117896
[TBL] [Abstract][Full Text] [Related]
54. Attitudes of nurses toward current and proposed vaccines for public programs: a questionnaire survey.
Gilca V; Boulianne N; Dubé E; Sauvageau C; Ouakki M
Int J Nurs Stud; 2009 Sep; 46(9):1219-35. PubMed ID: 19349047
[TBL] [Abstract][Full Text] [Related]
55. Vaccine adverse event reporting system reporting source: a possible source of bias in longitudinal studies.
Goodman MJ; Nordin J
Pediatrics; 2006 Feb; 117(2):387-90. PubMed ID: 16452357
[TBL] [Abstract][Full Text] [Related]
56. Vaccine shortages and suspect online pharmacy sellers.
Liang BA; Mackey TK
Vaccine; 2012 Jan; 30(2):105-8. PubMed ID: 22094281
[TBL] [Abstract][Full Text] [Related]
57. Performance of the United States Vaccine Injury Compensation Program (VICP): 1988-2019.
Thompson KM; Orenstein WA; Hinman AR
Vaccine; 2020 Feb; 38(9):2136-2143. PubMed ID: 31982259
[TBL] [Abstract][Full Text] [Related]
58. Wyeth Pharmaceutical's perspective on vaccine production.
Stiles GL
Md Med; 2005; 6(1):22-3. PubMed ID: 15869103
[No Abstract] [Full Text] [Related]
59. National Vaccine Injury Compensation Program: revised amount of the average cost of a health insurance policy--HRSA.
Fed Regist; 1998 Apr; 63(63):16264-5. PubMed ID: 10177760
[No Abstract] [Full Text] [Related]
60. Potential impact of acceleration of the pertussis vaccine primary series for infants.
Shinall MC; Peters TR; Zhu Y; Chen Q; Poehling KA
Pediatrics; 2008 Nov; 122(5):1021-6. PubMed ID: 18977982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
